Prof. Most is founder and CEO of AaviGen. He is responsible for the integration of science and commercial as well as for alliances and external relations more broadly. Prior to AaviGen, Prof. Most founded InoCard, a cardiovascular gene therapy start-up that was sold to uniQure N.V. and subsequently entered into a development alliance with Bristol-Myers Squibb. He also served as Managing Director of uniQure Germany and Senior Vice President for uniQure N.V. where he led a fully staffed R&D entity to direct the FDA and EMA legislation-compliant development of its lead gene therapy medicinal product towards IND and IMP status. Prof. Most heads the Molecular and Translational Cardiology Division at the University of Heidelberg. He received his scientific training at the University of Heidelberg, Duke University, and Thomas Jefferson University. He obtained his Medical Doctor and clinical training at the University of Heidelberg and the University of Lübeck.